<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094853/" ref="ordinalpos=413&amp;ncbi_uid=2954034&amp;link_uid=PMC3094853" image-link="/pmc/articles/PMC3094853/figure/F1/" class="imagepopup">Figure 1.  From: Unnatural Polyketide Analogues Selectively Target the HER <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> in Human Breast Cancer Cells. </a></div><br /><div class="p4l_captionBody">Schematic representation of HER2-mediated PI3K-Akt signaling pathway. Activation of HER2 initiates the activation of the cytoplasmic tyrosine kinase domain and subsequent events to activate downstream of PI3K and Akt. The activation of Akt suppresses apoptosis and stimulates the cell survival pathway.</div></div>